| Autor: |
Madison Nguyen, Amon Asgharpour, Dave L. Dixon, Arun J. Sanyal, Anurag Mehta |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
American Journal of Preventive Cardiology, Vol 17, Iss , Pp 100638- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2666-6677 |
| DOI: |
10.1016/j.ajpc.2024.100638 |
| Popis: |
Metabolic-dysfunction associated steatotic liver disease (MASLD) affects 1 out of every 3 individuals in the adult population and the disease prevalence is predicted to increase worldwide. Patients with MASLD are also burdened by cardiovascular disease, which is the leading cause of mortality in this population. Complex metabolic derangements such as insulin resistance and atherogenic dyslipidemia affect patients with MASLD. In patients with MASLD, treatment such as pharmacotherapy may be best directed towards improving the adverse concomitant metabolic disorders associated with MASLD, particularly the ones that may contribute to MASLD. Herein, we discuss conventional therapies that target cardiometabolic risk factors which have the potential to improve hepatic injury, and summarize emerging therapies that target hepatic receptors, fibrosis, and fatty acid oxidation in patients with MASLD. Given the relationship between hepatic injury which leads to MASLD, insulin resistance, and ultimately atherogenic dyslipidemia our review uniquely delves into the effects of conventional and emerging therapies for MASLD on plasma lipid parameters. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
